GSK
GSK invests $300m in 23andMe under drug development deal
GlaxoSmithKline (GSK) has formed a multi-year alliance with genetics firm 23andMe to carry out research and development for new medicines…
GSK gets priority review for Krintafel to prevent malaria relapse
GlaxoSmithKline (GSK) has gained the US Food and Drug Administration (FDA) priority review approval for its Krintafel (tafenoquine) to prevent…
GSK to divest tapinarof asset rights to Dermavant for £250m
GlaxoSmithKline (GSK) has signed an agreement to divest rights to tapinarof, one of its investigational drugs, to Dermavant Sciences, a…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox